Dimensional Fund Advisors LP acquired a new stake in Chiasma Inc (NASDAQ:CHMA) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 53,481 shares of the biotechnology company’s stock, valued at approximately $136,000. Dimensional Fund Advisors LP owned about 0.22% of Chiasma at the end of the most recent quarter.

Separately, ValuEngine upgraded Chiasma from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

Shares of Chiasma Inc (NASDAQ:CHMA) opened at $1.55 on Wednesday. Chiasma Inc has a fifty-two week low of $1.25 and a fifty-two week high of $2.95.

TRADEMARK VIOLATION NOTICE: “Dimensional Fund Advisors LP Acquires New Holdings in Chiasma Inc (CHMA)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://theolympiareport.com/2018/02/14/dimensional-fund-advisors-lp-acquires-new-holdings-in-chiasma-inc-chma.html.

About Chiasma

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Want to see what other hedge funds are holding CHMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chiasma Inc (NASDAQ:CHMA).

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.